The role of entecavir in preventing hepatitis B recurrence after liver transplantation
Article first published online: 28 OCT 2009
© 2009 The Authors. Journal compilation © 2009 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology and Blackwell Publishing Asia Pty Ltd.
Journal of Digestive Diseases
Volume 10, Issue 4, pages 321–327, November 2009
How to Cite
XI, Z. F., XIA, Q., ZHANG, J. J., CHEN, X. S., HAN, L. Z., WANG, X., SHEN, C. H., LUO, Y., XIN, T. Y., WANG, S. Y. and QIU, D. K. (2009), The role of entecavir in preventing hepatitis B recurrence after liver transplantation. Journal of Digestive Diseases, 10: 321–327. doi: 10.1111/j.1751-2980.2009.00403.x
- Issue published online: 28 OCT 2009
- Article first published online: 28 OCT 2009
- hepatitis B immunoglobulin;
- hepatitis B recurrence;
- liver transplantation
OBJECTIVE: Although hepatitis B recurrence after liver transplantation has been reduced to 0%–10% since the application of the combination therapy of hepatitis B immunoglobulin (HBIG) and lamivudine, the viral mutation resistance of lamivudine is still an obstacle to the outcome of liver transplantation. Here we evaluate the role of entecavir in preventing hepatitis B recurrence after liver transplantation.
Patients who received a liver transplantation for hepatitis B virus (HBV)-related end-stage liver disease in our center from March 2006 to December 2008 were enrolled in this study. All patients received entecavir (0.5 mg orally, daily) or lamivudine (100 mg orally, daily) together with a long-term low dosage of HBIG to prevent hepatitis B recurrence after transplantation. Serum viral markers (HBsAg, anti-HBs, HBeAg, anti-HBc and anti-HBe) and HBV-DNA level were determined.
RESULTS: Thirty patients receiving entecavir and 90 patients receiving lamivudine were matched with the same age and sex in both groups. No reinfection of hepatitis B was detected in the entecavir group. The hepatitis B surface antigen of patients in the entecavir group became negative within one week and no patient had any adverse effect relating to entecavir. There was no difference in the cumulative survival rate between the entecavir group and the lamivudine group (P > 0.05).
CONCLUSION: This study shows that entecavir combined with low dosages of HBIG is effective and safe in preventing hepatitis B recurrence after liver transplantation, but its long-term effect is still under investigation and a large-sample study will be carried out in the future.